BACKGROUND: The eyelids are more susceptible than other tissues to swelling, acute @entity32 , and resultant long-term damage. However, no precise, objective means of measuring eyelid swelling in the clinical setting has been developed. OBJECTIVES: The aims of this study were to assess the novel use of scanning and imaging technology for quantifying eyelid swelling and to use positive and negative controls to assess this new method for potential use in future clinical studies of eyelid swelling and pharmaceutical agents' effects on it. METHODS: This was a 1-visit, single-center, prospective, randomized, double-masked, placebo-controlled study using the conjunctival allergen challenge (CAC). After baseline examinations and eyelid scanning, medication was instilled as follows: @entity13205 0.1% ophthalmic solution in 1 eye and placebo in the other. An allergen solution to which @entity1 had a history of reaction was instilled in each eye 15 minutes after instillation of medication. Evaluations were performed for itching (3, 5, and 7 minutes after CAC), redness and chemosis (10, 15, 20, and 30 minutes), subjective eyelid evaluation (15 and 30 minutes), and 3-dimensional (3D) objective eyelid scan (15 and 30 minutes). RESULTS: One hundred seven @entity1 were randomized. Fifty-six @entity1 (35 @entity1 , 21 @entity1 ; mean age, 44.7 years) were evaluable for efficacy. Results of the objective and subjective evaluations of eyelid swelling were consistent, indicating significantly less eyelid swelling in @entity13205 -treated eyes than in those that received placebo (objective evaluation, P < 0.001 at 15 minutes, P < 0.017 at 30 minutes; subjective evaluation, P < 0.001 at 15 and 30 minutes). @entity1 rated eyelid swelling in the placebo eye as 2.31 times and 2.40 times greater than that in the @entity13205 -treated eye at 15 and 30 minutes, respectively. However, the digitally scanned eyelid swelling was calculated to be 5.65 times and 1.76 times greater in the placebo eye at the same respective time points. @entity2194 was observed in @entity13205 -treated eyes at all time points (P < 0.001). CONCLUSIONS: In this study, eyelid swelling was quantifiably measured with 3D imaging technology. In this model, the standard antiallergy medication @entity13205 , used as a positive control, significantly modulated eyelid swelling when used prophylactically. A negative control, artificial tears, did not significantly affect the @entity56 . These results concurred with subjective grading but offered a more precise assessment of eyelid swelling.

One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the @entity56 with contralateral use of XXXX and artificial tears.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['Reduction of ocular chemosis'] @entity13205 :: ('MESH:C074921', 'Chemical') :: ['olopatadine hydrochloride', 'olopatadine'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic eyelid-swelling reaction']
@entity13205 :: (MESH:C074921,Chemical) :: ['olopatadine']
